# Sutro Biopharma, Inc.: financial statements, quarterly

STRO · Nasdaq · CIK 1382101 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/stro.md) · [Financials](/companies/stro/financials.md) · [Filings](/companies/stro/filings.md) · [Insiders](/companies/stro/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/stro/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [16.9](/filings/0000950170-24-126407.md) | [114 d](/filings/0000950170-25-038884.md) | [13.0](/filings/0000950170-25-067072.md) | [25.7](/filings/0000950170-25-105219.md) | [8.5](/filings/0001193125-25-270036.md) | [14.8 d](/filings/0001193125-26-119873.md) | [17.4](/filings/0001193125-26-224170.md) | [63.7](/filings/0001193125-26-345748.md) | [9.7](/filings/0001193125-25-270036.md) | [11.6 d](/filings/0001193125-26-119873.md) | [14.5](/filings/0001193125-26-224170.md) | [9.8](/filings/0001193125-26-345748.md) |
| Research and development | $m | [45.7](/filings/0000950170-24-126407.md) | [53.8 d](/filings/0000950170-25-038884.md) | [56.9](/filings/0000950170-25-067072.md) | [62.0](/filings/0000950170-25-105219.md) | [62.1](/filings/0001193125-25-270036.md) | [71.0 d](/filings/0001193125-26-119873.md) | [51.6](/filings/0001193125-26-224170.md) | [38.3](/filings/0001193125-26-345748.md) | [39.9](/filings/0001193125-25-270036.md) | [36.6 d](/filings/0001193125-26-119873.md) | [36.6](/filings/0001193125-26-224170.md) | [31.7](/filings/0001193125-26-345748.md) |
| Operating income | $m | [(44.0)](/filings/0000950170-24-126407.md) | [43.2 d](/filings/0000950170-25-038884.md) | [(56.6)](/filings/0000950170-25-067072.md) | [(48.7)](/filings/0000950170-25-105219.md) | [(67.9)](/filings/0001193125-25-270036.md) | [(65.3) d](/filings/0001193125-26-119873.md) | [(68.5)](/filings/0001193125-26-224170.md) | [(3.3)](/filings/0001193125-26-345748.md) | [(48.5)](/filings/0001193125-25-270036.md) | [(38.0) d](/filings/0001193125-26-119873.md) | [(29.7)](/filings/0001193125-26-224170.md) | [(29.9)](/filings/0001193125-26-345748.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.8](/filings/0000950170-24-126407.md) | [15.8 d](/filings/0000950170-25-038884.md) | not reported | [0.0](/filings/0000950170-25-105219.md) | [0.0](/filings/0001193125-25-270036.md) | [2.4 d](/filings/0001193125-26-119873.md) | [0.0](/filings/0001193125-26-224170.md) | [(0.0)](/filings/0001193125-26-345748.md) | [0.0](/filings/0001193125-25-270036.md) | [(0.1) d](/filings/0001193125-26-119873.md) | [(0.0)](/filings/0001193125-26-224170.md) | [0.0](/filings/0001193125-26-345748.md) |
| Net income | $m | [(49.3)](/filings/0000950170-24-126407.md) | [31.1 d](/filings/0000950170-25-038884.md) | [(58.2)](/filings/0001193125-25-270036.md) | [(48.0)](/filings/0001193125-25-270036.md) | [(48.8)](/filings/0001193125-25-270036.md) | [(72.4) d](/filings/0001193125-26-119873.md) | [(76.0)](/filings/0001193125-26-345748.md) | [(11.5)](/filings/0001193125-26-345748.md) | [(56.9)](/filings/0001193125-25-270036.md) | [(46.8) d](/filings/0001193125-26-119873.md) | [(38.5)](/filings/0001193125-26-345748.md) | [(38.5)](/filings/0001193125-26-345748.md) |
| Diluted EPS | $ per share | [(0.81)](/filings/0000950170-24-126407.md) | not reported | [(0.59)](/filings/0000950170-25-105219.md) | [(0.59)](/filings/0000950170-25-105219.md) | [(0.59)](/filings/0001193125-25-270036.md) | not reported | [(9.08)](/filings/0001193125-26-224170.md) | [(1.35)](/filings/0001193125-26-345748.md) | [(0.67)](/filings/0001193125-25-270036.md) | not reported | [(2.94)](/filings/0001193125-26-224170.md) | [(2.33)](/filings/0001193125-26-345748.md) |
| Basic EPS | $ per share | [(0.81)](/filings/0000950170-24-126407.md) | not reported | [(0.59)](/filings/0000950170-25-105219.md) | [(0.59)](/filings/0000950170-25-105219.md) | [(0.59)](/filings/0001193125-25-270036.md) | not reported | [(9.08)](/filings/0001193125-26-224170.md) | [(1.35)](/filings/0001193125-26-345748.md) | [(0.67)](/filings/0001193125-25-270036.md) | not reported | [(2.94)](/filings/0001193125-26-224170.md) | [(2.33)](/filings/0001193125-26-345748.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [81.8](/filings/0000950170-24-126407.md) | [69.3](/filings/0000950170-25-038884.md) | [65.2](/filings/0000950170-25-067072.md) | [90.8](/filings/0000950170-25-105219.md) | [175](/filings/0001193125-25-270036.md) | [190](/filings/0001193125-26-119873.md) | [106](/filings/0001193125-26-224170.md) | [64.0](/filings/0001193125-26-345748.md) | [65.9](/filings/0001193125-25-270036.md) | [58.1](/filings/0001193125-26-345748.md) | [73.7](/filings/0001193125-26-224170.md) | [54.3](/filings/0001193125-26-345748.md) |
| Current assets | $m | [381](/filings/0000950170-23-063037.md) | [422](/filings/0000950170-25-038884.md) | [355](/filings/0000950170-24-058718.md) | [443](/filings/0000950170-24-096336.md) | [406](/filings/0000950170-24-126407.md) | [343](/filings/0001193125-26-119873.md) | [287](/filings/0000950170-25-067072.md) | [232](/filings/0000950170-25-105219.md) | [182](/filings/0001193125-25-270036.md) | [151](/filings/0001193125-26-345748.md) | [221](/filings/0001193125-26-224170.md) | [176](/filings/0001193125-26-345748.md) |
| Total assets | $m | [432](/filings/0000950170-23-063037.md) | [471](/filings/0000950170-25-038884.md) | [403](/filings/0000950170-24-058718.md) | [489](/filings/0000950170-24-096336.md) | [452](/filings/0000950170-24-126407.md) | [387](/filings/0001193125-26-119873.md) | [321](/filings/0000950170-25-067072.md) | [262](/filings/0000950170-25-105219.md) | [210](/filings/0001193125-25-270036.md) | [174](/filings/0001193125-26-345748.md) | [242](/filings/0001193125-26-224170.md) | [194](/filings/0001193125-26-345748.md) |
| Current liabilities | $m | [73.6](/filings/0000950170-23-063037.md) | [93.7](/filings/0000950170-25-038884.md) | [79.5](/filings/0000950170-24-058718.md) | [130](/filings/0000950170-24-096336.md) | [131](/filings/0000950170-24-126407.md) | [132](/filings/0001193125-26-119873.md) | [133](/filings/0000950170-25-067072.md) | [74.2](/filings/0000950170-25-105219.md) | [71.9](/filings/0001193125-25-270036.md) | [75.1](/filings/0001193125-26-345748.md) | [70.8](/filings/0001193125-26-224170.md) | [52.9](/filings/0001193125-26-345748.md) |
| Total liabilities | $m | [319](/filings/0000950170-23-063037.md) | [321](/filings/0000950170-25-038884.md) | [305](/filings/0000950170-24-058718.md) | [337](/filings/0000950170-24-096336.md) | [341](/filings/0000950170-24-126407.md) | [343](/filings/0001193125-26-119873.md) | [347](/filings/0000950170-25-067072.md) | [294](/filings/0000950170-25-105219.md) | [297](/filings/0001193125-25-270036.md) | [306](/filings/0001193125-26-345748.md) | [309](/filings/0001193125-26-224170.md) | [298](/filings/0001193125-26-345748.md) |
| Long-term debt | $m | not reported | [0.0](/filings/0000950170-24-035949.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [7.1](/filings/0000950170-23-063037.md) | [4.1](/filings/0000950170-24-035949.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [112](/filings/0000950170-24-126407.md) | [150](/filings/0001193125-26-119873.md) | [98.0](/filings/0001193125-25-270036.md) | [152](/filings/0001193125-25-270036.md) | [111](/filings/0001193125-25-270036.md) | [44.6](/filings/0001193125-26-345748.md) | [(25.8)](/filings/0001193125-26-345748.md) | [(32.1)](/filings/0001193125-26-345748.md) | [(87.3)](/filings/0001193125-25-270036.md) | [(132)](/filings/0001193125-26-345748.md) | [(66.9)](/filings/0001193125-26-345748.md) | [(103)](/filings/0001193125-26-345748.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent, us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(33.5) d](/filings/0000950170-24-126407.md) | [14.1 d](/filings/0000950170-25-038884.md) | [(64.7)](/filings/0000950170-25-067072.md) | [9.5 d](/filings/0000950170-25-105219.md) | [(64.5) d](/filings/0001193125-25-270036.md) | [(71.7) d](/filings/0001193125-26-119873.md) | [(67.9)](/filings/0001193125-26-224170.md) | [(44.7) d](/filings/0001193125-26-345748.md) | [(38.2) d](/filings/0001193125-25-270036.md) | [(26.4) d](/filings/0001193125-26-119873.md) | [(42.3)](/filings/0001193125-26-224170.md) | [(38.3) d](/filings/0001193125-26-345748.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [52.3](/filings/0000950170-23-063037.md) | [58.7](/filings/0000950170-24-058718.md) | [60.3](/filings/0000950170-24-096336.md) | [60.6](/filings/0000950170-24-126407.md) | [61.5](/filings/0000950170-25-067072.md) | [81.2](/filings/0000950170-25-105219.md) | [82.0](/filings/0001193125-25-270036.md) | [8.4](/filings/0001193125-26-224170.md) | [8.5](/filings/0001193125-26-345748.md) | [84.9](/filings/0001193125-25-270036.md) | [13.1](/filings/0001193125-26-224170.md) | [16.6](/filings/0001193125-26-345748.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,581,171 at 2026-08-07, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-345748.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.